EVALUATION OF NALMEFENE, AN ENDORPHIN ANTAGONIST, IN THE CONTROL OF APPETITE

该研究旨在评估纳美芬的疗效-- 第三代纳洛酮控制食欲。 初始 受试者是Prader-Willi综合征患者。 药物 在三周内逐步增加至40 mg/ 天 这些患者随后被随访了两个月， 门诊部，接受纳美芬两周， 与安慰剂交替使用两周。 最后一周， 临床中心进行了仔细评估。 无影响 在5名普拉德-威利（Prader-Willi） 综合征患者。 方案中止。

The study was designed to assess the efficacy of nalmefene--a third generation naloxone in the control of appetite. The initial subjects were Prader-Willi Syndrome patients. The medication was increased stepwise over a three week period to 40 mg per day. The patients were then followed for two months in the outpatient department, receiving nalmefene for two weeks, alternating with placebo for two weeks. A final week in the Clinical Center was used for careful evaluation. No effect of the medication was found on food intake in any of the 5 Prader-Willi syndrome patients. Protocol discontinued.